Perspective on OIG Guidelines for Pharmaceutical Companies: An Expert Interview With Arthur Palamara, MD
Laurie Barclay, MD Oct. 9, 2002 Editor’s Note: The Office of the Inspector General (OIG) is
Laurie Barclay, MD Oct. 9, 2002 Editor’s Note: The Office of the Inspector General (OIG) is
NEW YORK (Reuters Health) Oct 02 – Pulse-dye laser (PDL), intralesional steroids, and intralesional 5-fluorouracil (5-FU) appear
By Alicia Ault WASHINGTON (Reuters Health) Oct 03 – A panel of US government advisers on Thursday
NEW YORK (Reuters Health) Oct 03 – In children with atopic dermatitis, the appearance of house dust
By Will Boggs, MD NEW YORK (Reuters Health) Oct 04 – Major protocol deviations occur in two
NEW YORK (Reuters Health) Oct 04 – Adipose tissue may be a determinant of transforming growth factor-beta-1
Laurie Barclay, MD Oct. 7, 2002 The benefits of angiotensin-converting enzyme (ACE) inhibitors outweigh any minor
Laurie Barclay, MD Oct. 7, 2002 Results from the Multiple Outcomes of Raloxifene (MORE) trial suggest
By Will Boggs, MD NEW YORK (Reuters Health) Sept 30 – Active rheumatoid arthritis associated with elevated
Laurie Barclay, MD Oct. 1, 2002 In a multicenter, randomized trial reported in the Oct. 1
נא ציין כתובת דואר אלקטרוני שבה אתה מקבל דיוורי e-Med או זו שציינת בכרטיס האישי שלך.
קישור לאיפוס סיסמא נשלח למייל.
חזרה להתחברות